Published on March 5, 2013 at 6:42 AM
Writing in the Bill & Melinda Gates Foundation's "Impatient Optimists" blog, Gary Darmstadt, head of the Family Health Division of the foundation, examines the Jadelle Access Program, announced last week, which aims to "reduce the price [of Jadelle] and make this effective, long-acting, reversible contraceptive more available to more than 27 million women in the world's poorest countries." He continues, "Through an innovative approach, these public and private sector partners provide a volume guarantee for the product," and notes, "With this agreement, Bayer has reduced the price of Jadelle by more than half to $8.50 per unit in more than 50 countries that are urgently working to increase the availability of life-saving commodities" (3/1).
This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.